Oncolytics Biotech (ONCY) FCF Margin (2009 - 2020)

Oncolytics Biotech (ONCY) posted quarterly FCF Margin of 0.04% for Q3 2020, up 490.91% quarter-over-quarter from 0.01% in Q2 2020.

Oncolytics Biotech (ONCY) FCF Margin (2009 - 2020) Analysis & Trends

Oncolytics Biotech (ONCY) has reported FCF Margin for 7 consecutive years, with 0.04% the latest figure, recorded in Q3 2020.

In Q3 2020, FCF Margin changed N/A year-over-year to 0.04%; the TTM figure through Sep 2020 stood at 0.02% (up 2.0% YoY), while the FY2018 annual figure was 0.0%, changed N/A from the prior year.
FCF Margin improved to 0.04% in Q3 2020 per ONCY's latest filing, from 0.01% in the prior quarter.
Across five years, FCF Margin topped out at 220.9% in Q3 2018 and bottomed at 0.8% in Q2 2016.
Historically, FCF Margin has averaged 27.53% across 5 years, with a median of 0.01% in 2020.
Annual changes were most pronounced in 2017 — FCF Margin surged 80 bps — and 2020, when it decreased 4 bps.
Oncolytics Biotech's FCF Margin stood at 0.8% in 2016, then soared by 100 bps to 0.0% in 2017, then surged by 1573029528 bps to 220.9% in 2018, then sank by 100 bps to 0.05% in 2019, then dropped by 17 bps to 0.04% in 2020.
Business Quant data shows ONCY's FCF Margin at 0.04% in Q3 2020, 0.01% in Q2 2020, and 0.02% in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.57 Bn	131.72 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	13.35%
3	Argenx Se	65.44 Bn	60.25 Bn	1.37 Bn	-
4	Moderna	60.06 Bn	54.93 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.89 Bn	28.58 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.11 Bn	9.72 Bn	668.28 Mn	41.07%
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	70.82%
10	Oncolytics Biotech	98.53 Mn	98.53 Mn	-	-

Download Data